Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Monday. The firm issued a sell rating on the stock.

Oragenics Price Performance

OGEN stock opened at $0.32 on Monday. Oragenics has a 1 year low of $0.28 and a 1 year high of $7.74. The stock has a market cap of $1.79 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. The company has a 50 day simple moving average of $0.45 and a 200 day simple moving average of $1.06.

Oragenics (NYSE:OGEN) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new stake in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is owned by hedge funds and other institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.